Liquidia books $236.3M quarterly loss as settlement cost overshadows 31% sales growth
YUTREPIA brought in $222.7M in the third quarter, but a $389.7M charge tied to the October deal with United Therapeutics pushed Liquidia into the red.
Liquidia reported third-quarter 2026 results on 10 November. Sales of its inhaled treprostinil dry-powder product YUTREPIA reached $222.7M, up 31% on the second quarter. Adjusted EBITDA for the period was $140.5M.
The bottom line told a different story. Liquidia recorded a $389.7M charge connected to its October agreement with United Therapeutics, which resolves all litigation between the two companies. After that charge, the quarterly loss under US GAAP was $236.3M. The material reviewed does not set out the settlement's other terms beyond the charge.
Two regulatory items were also disclosed. YUTREPIA has been granted FDA Fast Track designation in SSc-RP. Separately, a Prior Approval Supplement is pending at the agency to take the PH-ILD indication off the product's label. The source material does not explain the reasoning behind the label request or say when the FDA might respond.
On the pipeline, Liquidia said 11 studies are under way or planned, among them trials of L606. No further trial details were available.
Why it matters
- The gap between $140.5M adjusted EBITDA and a $236.3M GAAP loss shows how far a single legal settlement can distort headline earnings; the charge is a one-off item tied to the dispute.
- With all litigation against United Therapeutics now resolved, Liquidia no longer has that dispute hanging over it, though the full financial terms are not disclosed in the material reviewed.
- The pending label change that would remove PH-ILD is the item to watch, as it would alter the product's approved scope; the reasons and timing are not stated.
- Fast Track in SSc-RP is a development-stage designation, not an approval, so it signals regulatory engagement rather than a new revenue source.
Company's press release (SEC filing): Liquidia Corp ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
